Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status.
Avraham Travers, Azim Jalali, Stephen Begbie, Christine Semira, Suzanne Kosmider, Sumitra Ananda, Rachel Wong, Margaret Lee, Jeremy Shapiro, Matthew Burge, Desmond Yip, Javier Torres, Brigette Ma, Louise Nott, Andrew Dean, Jeanne Tie, Adnan Khattak, Stephanie Lim, Hui-Li Wong, Peter Gibbs
Clinical Colorectal Cancer | Published : 2021
BACKGROUND: The management of metastatic colorectal cancer patients with a poor performance status (PS) continues to be a clinical dilemma, with the potential activity and safety of treating this population remaining poorly understood. Few of these patients are enrolled onto clinical trials, and poor PS is often multifactorial. PATIENTS AND METHODS: We analyzed the Treatment of Recurrent and Advanced Colorectal Cancer registry to describe treatment practices and outcomes in poor (Eastern Cooperative Oncology Group [ECOG] PS 2) and very poor PS (ECOG PS > 2) patients to explore the relationship between age, tumor burden, comorbidities, and PS, and to evaluate the benefit of systemic therapy. ..View full abstract